The "Addivosome": A Moscow Team Proposes Addiction Is a Disease of Pathological Biomolecular Condensates
- Moscow Research and Practical Centre on Addictions proposes a novel cellular mechanism for relapse vulnerability — the "Addivosome," a pathological biomolecular condensate formed in the postsynaptic density during repeated drug exposure [RU]
- The model reframes addiction from a disorder of synaptic plasticity to a phase-separation disorder — the post-synaptic density undergoes maladaptive "maturation" into a rigid, self-maintaining state that enforces aberrant pathway cross-talk
- Four testable predictions proposed: proteomic signatures via proximity labeling, optogenetic clustering/dispersal experiments, FRAP-based reliquefaction screening, and autophagy-tethering chimeras for selective clearance
- Published in Neuroscience and Biobehavioral Reviews (Tier 1, IF ~10) — a theoretical model with explicit translational targets for future pharmacotherapy
Addiction neuroscience has long operated on a rewiring model: chronic drug exposure reshapes synaptic connections, and relapse is the reactivation of those pathological circuits. This Moscow-based theoretical paper proposes something different — and physically stranger. The culprit is not just what synapses connect to what, but what happens inside the synapse at the molecular level. Drugs push the postsynaptic density through a phase transition, from a dynamic liquid-like state to a rigid, self-maintaining condensate. Relapse memory is not written in wiring; it is written in frozen protein architecture.
Why biomolecular condensates matter
Biomolecular condensates — membraneless assemblies formed by phase separation — are a recent frontier in cell biology. They form reversibly, concentrate specific proteins, and regulate biochemical reactions without membrane barriers. The healthy postsynaptic density is one such condensate: dynamic, responsive, reorganizing in response to synaptic activity.
The Addivosome hypothesis states that repeated cycles of intoxication, withdrawal, and abstinence push this normally-dynamic condensate toward a rigid end state. Dopamine and glutamate co-activation stabilizes specific protein interactions. Over time, the condensate loses its ability to disassemble and reorganize. It becomes self-maintaining — a cellular mnemonic of addiction that persists even during long abstinence and enforces relapse when environmental cues reactivate it.
The testable predictions
The paper does not just propose a model — it specifies how to falsify it. Four experimental pathways:
- Proximity labeling to define state-specific proteomic signatures of the Addivosome
- Optogenetic clustering/dispersal to test whether acute condensate manipulation causes addiction-like or abstinence-like states
- FRAP (Fluorescence Recovery After Photobleaching) to screen compounds that restore liquid-like mobility — "reliquefaction"
- Autophagy-tethering chimeras to selectively clear the pathological condensate while sparing physiological ones
This is the structure of rigorous theoretical work: a novel mechanism combined with the tools to disprove it.
For your practice
For clinicians working in addiction treatment: this paper does not change today's practice, but it reframes why treatment-resistant relapse exists. If the Addivosome model is correct, standard cognitive-behavioral approaches target the circuit level while the cellular substrate remains frozen. Future pharmacotherapy may aim at "reliquefaction" — restoring the dynamic state of synaptic assemblies. For researchers: this is a hypothesis-generating paper that deserves empirical testing. The Moscow group working at the intersection of addiction psychiatry and molecular neuroscience is positioned to do that testing.
Addiction is not just rewired circuits. It may be rigidified protein architecture — a frozen synaptic condensate that remembers drug exposure at the molecular level.
Theoretical model, not yet empirically tested. All predictions remain to be validated. The selectivity challenge — distinguishing pathological from physiological condensates — is acknowledged but not solved. Translational path from model to human therapeutic is long.